ProMIS Neurosciences Inc. (PMN) stock
PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.21−0.10 (-3.02%)
Close on Nov 17, 2026Market cap $28.79MP/E –Yield –
ProMIS Neurosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ProMIS Neurosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$42.11M. For fiscal 2025 it was -$28.12M. The highest annual figure on record is -$9.31M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$28.12M | – |
| FY2024 | Dec 31, 2024 | -$27.18M | – |
| FY2023 | Dec 31, 2023 | -$10.84M | – |
| FY2022 | Dec 31, 2022 | -$17.03M | – |
| FY2021 | Dec 31, 2021 | -$9.31M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.64M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.03M | – |
See a number that looks wrong?